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ORIGINAL ARTICLE

The phosphorylated prodrug FTY720 is a histone deacetylase
inhibitor that reactivates ERα expression and enhances
hormonal therapy for breast cancer
NC Hait1, D Avni1, A Yamada2, M Nagahashi2, T Aoyagi2, H Aoki2, CI Dumur3, Z Zelenko4, EJ Gallagher4, D Leroith4, S Milstien1,
K Takabe2 and S Spiegel1
Estrogen receptor-α (ERα)-negative breast cancer is clinically aggressive and does not respond to conventional hormonal therapies.
Strategies that lead to re-expression of ERα could sensitize ERα-negative breast cancers to selective ER modulators. FTY720
(ﬁngolimod, Gilenya), a sphingosine analog, is the Food and Drug Administration (FDA)-approved prodrug for treatment of multiple
sclerosis that also has anticancer actions that are not yet well understood. We found that FTY720 is phosphorylated in breast cancer
cells by nuclear sphingosine kinase 2 and accumulates there. Nuclear FTY720-P is a potent inhibitor of class I histone deacetylases
(HDACs) that enhances histone acetylations and regulates expression of a restricted set of genes independently of its known effects
on canonical signaling through sphingosine-1-phosphate receptors. High-fat diet (HFD) and obesity, which is now endemic,
increase breast cancer risk and have been associated with worse prognosis. HFD accelerated the onset of tumors with more
advanced lesions and increased triple-negative spontaneous breast tumors and HDAC activity in MMTV-PyMT transgenic mice. Oral
administration of clinically relevant doses of FTY720 suppressed development, progression and aggressiveness of spontaneous
breast tumors in these mice, reduced HDAC activity and strikingly reversed HFD-induced loss of estrogen and progesterone
receptors in advanced carcinoma. In ERα-negative human and murine breast cancer cells, FTY720 reactivated expression of silenced
ERα and sensitized them to tamoxifen. Moreover, treatment with FTY720 also re-expressed ERα and increased therapeutic
sensitivity of ERα-negative syngeneic breast tumors to tamoxifen in vivo more potently than a known HDAC inhibitor. Our work
suggests that a multipronged attack with FTY720 is a novel combination approach for effective treatment of both conventional
hormonal therapy-resistant breast cancer and triple-negative breast cancer.
Oncogenesis (2015) 4, e156; doi:10.1038/oncsis.2015.16; published online 8 June 2015

INTRODUCTION
The majority of breast tumors express the estrogen receptor-α
(ERα) that plays important roles in breast cancer pathogenesis and
progression, and hormonal therapies such as tamoxifen (TAM) are
the ﬁrst line of adjuvant therapy.1,2 Unfortunately, 30% of these
patients will ultimately fail therapy because of de novo or acquired
resistance. Moreover, patients with ER, progesterone receptor (PR)
and human epidermal growth factor receptor 2 (also known as
ErbB-2) triple-negative breast cancer, which is aggressive with
high recurrence, metastatic and mortality rates,3 do not respond
to hormonal therapies and have limited treatment options.
Epidemiological and clinical studies indicate that obesity, which
is now endemic, increases breast cancer risk and is associated with
worse prognosis4 that may be due in part to the high frequency of
triple-negative breast cancer and ineffectual hormonal therapy.5
As hormonal therapy is so effective with relatively few side effects,
the possibility of reversing hormonal unresponsiveness is an
appealing treatment approach. Histone deacetylases (HDACs) are
negative regulators of ERα transcription, and HDAC inhibitors,
including suberoylanilide hydroxamic acid (SAHA, vorinostat) and
trichostatin A, have been shown to reactivate ERα expression in

ERα − negative breast cancer cells and reverse TAM resistance in
preclinical studies.6–8 Encouragingly, in phase II clinical trials, the
combination of vorinostat and TAM showed promising activity in
reversing hormone resistance.9
FTY720 (ﬁngolimod), the Food and Drug Administration (FDA)
approved prodrug for the treatment of multiple sclerosis, is
phosphorylated in vivo by sphingosine kinase 2 (SphK2) to its
active form FTY720-phosphate (FTY720-P), a mimetic of
sphingosine-1-phosphate (S1P) and an agonist of four S1P
receptors (S1PRs) that interferes with immune cell trafﬁcking by
inducing internalization and degradation of S1PR1.10 However,
FTY720 has strong anticancer effects in vitro and in vivo in various
types of cancers including breast11,12 that are not well understood
independently of its effects on immune cell trafﬁcking.13 Although
some of its actions have been attributed to FTY720-P acting as a
functional antagonist of S1PR1, reducing persistent activation of
the transcription factor STAT3 (signal transducer and activator of
transcription 3) important in malignant progression,14–16 others
have shown that the unphosphorylated FTY720 is an activator of
protein phosphatase 2A, a tumor suppressor that is inactivated in
many cancers.17,18 However, our recent study suggests that
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FTY720-P and not FTY720 binds and inhibits recombinant class I
HDACs.19 Because it is generally believed that FTY720 in cancer
cells is phosphorylated at the plasma membrane by SphK2 to form
FTY720-P that acts via S1PRs, we asked where FTY720 is
phosphorylated in breast cancer cells and whether FTY720-P also
inhibits HDACs in these cells and in tumors to regulate histone
acetylation and gene expression, and can be used to re-express
ERα in ER-negative aggressive breast carcinoma for hormonal
therapies.
RESULTS
SphK2 produces FTY720-P in the nucleus of breast cancer cells
that inhibits class I HDACs
Following treatment with FTY720, an analog of sphingosine,
FTY720-P is produced and accumulates over time in the nucleus of
human and murine breast cancer cells in agreement with
the predominant nuclear localization of SphK2 in these cells
(Figures 1a, c, and f). Nuclear S1P levels were concomitantly
decreased by almost twofold in these cell lines after FTY720
treatment because of decreased phosphorylation of the endogenous substrate sphingosine (Figures 1a and c). Interestingly,

although it is generally assumed that most of the actions of the
phosphorylated active form of FTY720 are at the plasma
membrane to modulate S1PR signaling,10 much more FTY720-P
was present in cells than secreted into the media where it can
interact with S1PRs (Figures 1b and d). Overexpression of SphK2
robustly increased the formation of nuclear FTY720-P by 420-fold
in MDA-MB-231 cells (Figure 1e) and 100-fold in MCF7 cells
(Figure 1g), whereas catalytically inactive SphK2G212E had no
signiﬁcant effect on phosphorylation of FTY720 or formation
of nuclear S1P. In agreement with our previous results showing
that FTY720-P inhibits recombinant class I HDACs,19 we observed
that FTY720-P but not FTY720 itself inhibited endogenous class I
HDACs (HDAC1–3 and HDAC8) immunoprecipitated from nuclear
extracts with the corresponding antibodies as potently as the pan
HDAC inhibitor SAHA (Supplementary Figure S1). However, in
contrast to SAHA that inhibited class II HDAC7, FTY720-P did not.
Phosphorylated FTY720 enhances histone acetylations and
regulates gene expression independently of S1PRs
Because the majority of FTY720-P is produced in the nucleus of
breast cancer cells where its target HDACs are located, we next
examined its effects on histone acetylation. Concomitant with

Figure 1. FTY720-P is produced in the nucleus of breast cancer cells by SphK2. Breast cancer cell lines, murine 4T1 (a, b), human MDA-MB-231
(c, d) and human MCF7 (f) were treated with 5 μM FTY720. (a, c) Nuclear levels of FTY720-P and S1P were determined by liquid
chromatography, electrospray ionization/tandem mass spectrometry (LC-ESI-MS/MS) at the indicated times. Equal amounts of protein from
nuclear and cytosolic fractions were analyzed by immunoblotting with SphK2 antibody. Antibodies against histone H3 or laminA/C and
tubulin were used as nuclear and cytosol markers. (b, d) Total intracellular and secreted FTY720-P were determined in 4T1 cells after 8 h and
MDA-MB-231 cells after 6 h of FTY720 treatment, respectively. MDA-MB-231 cells (e) and MCF7 cells (g) transfected with vector, SphK2 or
catalytically inactive SphK2G212E (ciSphK2) were treated with vehicle or 5 μM FTY720 for 6 and 24 h, respectively. Nuclear levels of FTY720-P and
S1P were determined by LC-ESI-MS/MS. Data are mean ± s.d. *P o0.005 compared with vector; #P o0.005 compared with vehicle. Equal
expression of nuclear SphK2 was conﬁrmed by immunoblotting.
Oncogenesis (2015), 1 – 11
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increased nuclear FTY720-P (Figure 1), FTY720 increased acetylation of speciﬁc lysines of histone H3, H4 and H2B in MCF7 and
4T1 cells (Figures 2a and b). Similar results were found with MDAMB-231 cells (Supplementary Figure S2a). In order to demonstrate
that these effects are because of the intranuclear action of
FTY720-P, experiments were carried out with puriﬁed MCF7 nuclei
devoid of S1PRs. FTY720-P more potently than S1P enhanced
histone acetylation in these nuclei (Figure 2c). Treatment of MCF7
cells with the SphK2 inhibitor K145 reduced FTY720-mediated
histone acetylation (Supplementary Figure S2b). Importantly,
addition of FTY720 itself also increased histone acetylation in
these nuclei in a SphK2-dependent manner, as this effect was
further enhanced by overexpression of SphK2 (but not catalytically
inactive SphK2G212E) (Figure 2d) and was prevented by its
downregulation (Figure 2f). These effects correlated with the
extent of formation of FTY720-P (Figures 2e and g).
To conclusively demonstrate that the effects on histone
acetylation are due to direct intranuclear action of FTY720-P on
HDAC activity independently of canonical signaling through
S1PRs, cells were treated with FTY720-P that activates all S1PRs
except S1PR2.20 Although treatment of cells with FTY720-P, as
expected, increased S1PR-mediated phosphorylation of ERK1/2, it
did not induce signiﬁcant changes in histone acetylation or in
HDAC activity, in contrast to the signiﬁcant effects of treatment
with FTY720 or SAHA (Figures 2h and i).
Microarray analysis also indicated that the effects of FTY720 on
gene expression in breast cancer cells are clearly distinguished
from S1P receptor occupancy (Figure 3a). Unsupervised cluster

analysis on 22 277 probe sets as well as supervised hierarchical
cluster analyses demonstrated that there were no major
differences in the clustering of the gene expression proﬁles
between the naive, vehicle-treated and S1P-treated groups,
whereas signiﬁcant differences were observed in gene clustering
between them and the FTY720- and SAHA-treated groups
(Figure 3a). Although activation of S1PRs did not signiﬁcantly
alter gene expression, FTY720 treatment signiﬁcantly changed the
proﬁles of 713 genes. In comparison, SAHA signiﬁcantly altered
expression of 3166 genes, of which 276 were common to FTY720
(Figure 3b). The gene ontology analysis revealed that the majority
of the commonly affected genes were related to transcription
followed by lipid and steroid biosynthesis, transport and metabolic processes (Figure 3c). In addition, regulation of cell growth
and angiogenesis genes was also prominent. Together, these
results indicate that breast cancer cells take up FTY720 and that
FTY720-P produced in the nucleus by SphK2 inhibits class I HDACs
and increases speciﬁc histone acetylations and regulates expression of a restricted subset of gene programs independently
of S1PRs.
FTY720 treatment suppresses development and progression of
spontaneous breast tumors in HFD-fed MMTV-PyMT transgenic
mice
Aberrant expression of class I HDACs and dysregulation of global
histone acetylations has been found in a many cancers, including
breast, and HDACs are promising targets in cancer therapeutics

Figure 2. Nuclear FTY720-P enhances speciﬁc histone acetylations in breast cancer cells. MCF7 cells (a) and 4T1 cells (b) were treated with
FTY720 (5 μM) for the indicated times. Histone acetylations in nuclear extracts were detected by immunoblotting with antibodies to speciﬁc
histone acetylation sites. (c) Puriﬁed nuclei from naive MCF7 cells were incubated for the indicated times with vehicle, S1P (1 μM) or FTY720-P
(1 μM) and histone acetylations determined. (d, e) Puriﬁed nuclei were isolated from MCF7 cells transfected with vector, SphK2 or ciSphK2 and
treated with FTY720 (1 μM) for 15 min. (f, g) Puriﬁed nuclei were isolated from MCF7 cells transfected with siControl or siSphK2 and incubated
with the indicated concentrations of FTY720 for 15 min. Histone acetylations were determined by immunoblotting (d, f) and levels of FTY720P by liquid chromatography, electrospray ionization/tandem mass spectrometry (LC-ESI-MS/MS) (e, g). *P o0.05. (h, i) Naive MCF7 cells were
treated with vehicle, FTY720-P (100 nM), FTY720 (1 μM) or SAHA (2 μM) for 2 h, nuclear extracts were analyzed by western blotting with the
indicated antibodies (h) and HDAC activity measured and expressed as arbitrary ﬂuorescence units (AFU) (i). *P o0.001.
Oncogenesis (2015), 1 – 11
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Figure 3. Microarray analysis of genes regulated by FTY720 and SAHA. Gene expression in naive MCF7 cells or MCF7 cells treated with vehicle,
S1P (100 nM), FTY720 (1 μM) or SAHA (1 μM) for 24 h was determined by microarray analyses. (a) Heatmap showing supervised hierarchical
clustering of 713 genes differentially expressed in FTY720-treated cells compared with naive. Expression level of a given gene is indicated by
red (high) and green (low). Note that not all of the genes differentially regulated by SAHA are shown. (b) Venn diagram of genes differentially
regulated by FTY720 and SAHA. (c) The gene ontology (GO) Biological Process analyses of 276 common probe sets regulated by SAHA and
FTY720 treatment ranked for biological processes.

(reviewed in refs 21–24). Therefore, it was of interest to examine
whether the HDAC inhibitory activity of FTY720-P could mitigate
breast cancer development in a mouse model. Because diet,
particularly fat intake, contributes to the development and
progression of breast cancer and has been associated with worse
prognosis,4,5,25 MMTV-PyMT transgenic mice, which spontaneously develop breast cancer that closely mimics progression
of the human disease,26,27 were fed a high-fat diet (HFD). Female
PyMT transgenic mice on a normal chow diet spontaneously
developed palpable mammary tumors by 7.5 weeks (Figure 4a). In
agreement with others,28,29 feeding a HFD accelerated the onset
of tumors that were palpable by 6 weeks (Figure 4a) and increased
tumor multiplicity and size (Figures 4a and b). Although FTY720
administration decreased tumor burden without affecting onset in
mice on normal diet (Figure 4a), it signiﬁcantly increased the
latency for appearance of palpable tumors to 7.5 weeks and
dramatically suppressed tumor development in mice on HFD
(Figures 4a–c). In addition, HFD-fed PyMT mice exhibited more
advanced mammary carcinogenic lesions with poorly differentiated malignant cells of dissimilar cell shape and size (Figure 4d).
These changes were all mitigated by FTY720 treatment. Consistent
with the profound effect on tumor size, there was a signiﬁcant
increase in proliferation determined by Ki67 staining in the mice
fed HFD compared with normal diet, which was decreased by
FTY720 (Figures 4d and e). Conversely, TUNEL (terminal
Oncogenesis (2015), 1 – 11

deoxynucleotidyl transferase dUTP nick end labeling) staining
revealed a large increase in apoptotic cells in tumors from FTY720treated MMTV-PyMT transgenic mice (Figures 4d and e).
FTY720 treatment reverses HFD-induced HDAC activity and loss of
estrogen and progesterone receptors in advanced carcinoma
In agreement with the advanced carcinoma observed in animals
fed with HFD and consistent with a previous report,29 expression
of cyclin D1 was elevated (Figures 4d and 5a) and immunohistochemistry revealed high intensity of cyclin D1-positive clusters
within these tumors (Figure 4d). In contrast, ERα protein and
mRNA as well as PR mRNA were signiﬁcantly reduced (Figure 5a
and f), all of which are associated with poor prognosis in human
breast cancers.30 Notably, these characteristics of advanced
tumorigenic mammary lesions were reversed by FTY720 administration to the HFD-fed transgenic mice (Figure 5b). Moreover,
FTY720 treatment clearly induced nuclear ERα expression
(Figure 5b, c, and f). Intriguingly, HFD reduced acetylation of H3K9, H4-K5 and H2B-K12 in breast tumors that corresponded with
increased nuclear HDAC activity (Figures 5a,d). Conversely, FTY720
administration dramatically increased these speciﬁc histone
acetylations determined by immunoblotting (Figure 5b) and
conﬁrmed by immunohistochemical staining of H3-K9ac in
mammary tumors (Figure 5c). FTY720 also reduced HDAC activity
in breast tumors (Figure 5d), concomitant with marked production
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Figure 4. FTY720 treatment suppresses advanced tumorigenic mammary lesions in HFD-fed PyMT transgenic mice. Female PyMT transgenic
mice were fed with a normal diet (ND) or a Western HFD, and were treated daily with saline or FTY720 (1 mg/kg) by gavage starting after
weaning. (a) Tumor volumes were determined at the indicated times. (b) Representative images of 10-week-old female PyMTTg mice fed
with ND or HFD without or with FTY720. Note the difference in the size of the tumors in the mammary pads. (c) Tumor volumes and
weights were determined at 11 weeks. (d, e) Tumor sections were stained with hematoxylin and eosin (H&E), proliferation determined
by Ki67 staining, apoptosis by TUNEL and cyclin D1 expression determined by immunohistochemistry. Scale bars: 200 μm and 100 μm,
as indicated. (e) Quantiﬁcation of Ki67- and TUNEL-positive cells. Data are mean ± s.e.m. #Po 0.05 compared with ND; *Po0.05 compared
with HFD.

of nuclear FTY720-P compared with FTY720 (Figure 5e) and
increased mRNA levels of ERα and PR, without affecting expression
of ErbB2 (Figure 5f). Interestingly, in tumor-free mammary fat pads
from MMTV-PyMT transgenic mice or from naive C57BL/6 mice,
HFD reduced HDAC activity and increased histone acetylations
(Supplementary Figure S3).
FTY720 sensitizes triple-negative breast cancer cells to TAM by
reactivation of silenced ERα expression
HDACs are negative regulators of the ERα transcriptional complex
and HDAC inhibitors have been shown to epigenetically restore
ERα expression and reverse TAM resistance in hormone-resistant

breast cancer cells6,7,31,32 and in preclinical animal studies.33,34
As we found that FTY720 is phosphorylated in the nucleus of ERαnegative MDA-MB-231 and 4T1 breast cancer cells by SphK2
(Figure 1) and that FTY720-P is a potent class I HDAC inhibitor, we
asked whether it induces ERα re-expression in ERα-negative breast
cancer. Although FTY720 alters expression of many fewer genes
than SAHA (Figure 3c), FTY720 more potently than SAHA
enhanced ERα expression in 4T1 cells (Figure 6a), whereas in
MDA-MB-231 cells, it enhanced ERα mRNA and protein expression
to the same extent as SAHA (Figures 6b and c). Similar to SAHA,
FTY720 also enhanced expression of PR, one of the ERα target
genes (Figures 6b and c). As expected, neither SAHA nor FTY720
had a signiﬁcant effect on expression of ERβ (Figure 6b). Moreover,
Oncogenesis (2015), 1 – 11
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Figure 5. FTY720 treatment reverses HFD-induced loss of estrogen and progesterone receptors in PyMT transgenic mice. Female PyMT
transgenic mice were fed with a normal diet (ND) or a Western HFD, and were treated daily with saline or FTY720 (1 mg/kg) by gavage starting
after weaning (n = 5 each), as indicated. (a, b) Nuclear extracts from tumors were analyzed by western blotting with the indicated antibodies.
(c) Representative images of tumor sections immunostained with anti-ERα or anti-H3-K9ac antibodies. Scale bars: 20 μm. (d) HDAC activity in
nuclear extracts of tumors was determined and expressed as arbitrary ﬂuorescence units. (e) FTY720 and FTY720-P levels in nuclear extracts of
tumors from mice on HFD treated with FTY720 were measured by liquid chromatography, electrospray ionization/tandem mass spectrometry
(LC-ESI-MS/MS). (f) ERα, PR and ErbB2 mRNA levels in tumors were quantiﬁed by quantitative real-time PCR (QPCR) and normalized to Gapdh.
Data are mean ± s.e.m. *P o0.05 compared with ND; #Po 0.05 compared with HFD.

chromatin immunoprecipitation assays revealed that FTY720, even
more potently than SAHA, enhanced association of acetylated
histone H3 at the ERα promoter (Figure 6d), indicating that
reactivation of ERα expression correlates with ERα promoter
hyperacetylation. In agreement, treatment of these ERα-negative
cells with E2 enhanced their proliferation only in the presence of
FTY720 (Figure 6e). We next examined whether FTY720, which
restores ERα expression in ERα-negative breast cancer cells, could
also induce sensitivity to TAM, an ERα antagonist. As expected,
TAM alone at concentrations up to 10 μM did not inhibit growth of
Oncogenesis (2015), 1 – 11

MDA-MB-231 cells (Figure 6f). Like other HDAC inhibitors,6,31,32
FTY720 reduced growth in a concentration-dependent manner
and importantly sensitized the cells to TAM. For example,
although a concentration of 2.5 μM TAM or FTY720 alone only
reduced growth of MDA-MB-231 cells by 9.3% or 29.3%,
respectively, when combined, cell growth was inhibited by
463% (Figure 6f), with a Synergistic Index of 0.23. Similarly, in
highly metastatic ERα-negative 4T1 murine mammary carcinoma
cells, FTY720 also greatly enhanced the growth inhibitory effect of
TAM (Figure 6g), with a Synergistic Index of 0.23.
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Figure 6. FTY720 induces ERα expression in ERα-negative human and murine breast cancer cells and sensitizes them to tamoxifen. 4T1 (a) and
MDA-MB-231 (b) cells were treated with FTY720 (5 μM) or SAHA (1 μM) for 24 h. ERα, PR and ERβ mRNA levels were determined by quantitative
real-time PCR (QPCR) and normalized to GAPDH. (c) Proteins in MDA-MB-231 nuclear extracts were analyzed by immunoblotting with the
indicated antibodies. LaminA/C was used as a loading control. (d) MDA-MB-231 cells were subjected to chromatin immunoprecipitation (ChIP)
analyses with antibodies to H3-ac, H3 or normal rabbit IgG, as indicated. The precipitated DNA was analyzed by real-time PCR with primers
amplifying the core promoter sequence of the ERα gene. Relative binding to the promoter is expressed as fold enrichment compared with
input. Data are mean ± s.d. *P o0.003 compared with vehicle. (e) MDA-MB-231 cells were treated with FTY720 (1 nM) without or with 10 nM E2
for the indicated days and cell proliferation was determined by WST assay. (f, g) MDA-MB-231 cells (f) or 4T1 cells (g) were treated with the
indicated concentrations of TAM or FTY720, or with 2.5 μM FTY720 with increasing concentrations of TAM for 48 h and cell proliferation
determined. Data are expressed as % of untreated control.

FTY720 increases therapeutic sensitivity of ERα-negative syngeneic
breast tumors to TAM
As we have found that FTY720 treatment induces functional ERα
reactivation and sensitizes ERα-negative breast cancer cells to
TAM in vitro, we sought to determine whether FTY720 also
enhances antiestrogen therapy in vivo. We utilized a syngeneic
mouse metastatic breast cancer model instead of conventional
xenografts in immunocompromised nude mice that more
accurately mimics human breast cancer.35,36 ERα-negative
4T1 cells were orthotopically implanted into the second mammary
fat pad of immunocompetent mice and randomized to insure
similar tumor burdens before treatment. 4T1 cells produced large
primary tumors in the chest mammary fat pad that were not
signiﬁcantly reduced by TAM administration (Figure 7a). Orally
administered FTY720 reduced tumor growth, an effect that was
signiﬁcantly potentiated by coadministration of TAM (Figures 7a
and b). Strikingly, FTY720 enhanced the antitumor efﬁcacy of TAM
more than SAHA. TUNEL staining also revealed a large increase in
apoptotic cells in tumors from FTY720- plus TAM-treated mice as
compared with tumors from mice treated with each separately
(Figure 7c). Immunohistochemical analysis revealed that nuclear
expression of ERα was increased in tumors from FTY720-treated
mice that was more prominent when combined with TAM than
even in tumors from mice treated with the combination of SAHA
and TAM (Figure 7d). Consistent with the decreased nuclear HDAC
activity in tumors from animals treated with FTY720 or SAHA
(Figure 7e), acetylation of histone H3-K9, H4-K5 and H2B-K12 was
increased in these tumors (Figure 7g), leading to re-expression of

ERα (Figures 7f and g). Taken together, these data suggest that
FTY720 induces epigenetic ERα reactivation in vivo to enhance
hormonal therapy of ERα-negative breast cancer.
DISCUSSION
Hormonal therapies, including selective estrogen receptor modulators and aromatase inhibitors, are the standards of care for
treatment of ER-positive breast cancer. However, development of
resistance to hormone therapies in advanced breast cancer is a
major obstacle. Therefore, epigenetic reactivation of silenced ERα
expression by HDAC inhibitors has emerged as an attractive
potential mode of therapy for these breast cancer patients.9
Moreover, treatment of triple-negative breast cancer, which has
poor prognosis, remains challenging because the tumors are more
aggressive and resistant to hormonal therapy.30 Epigenetic
modiﬁcations are responsible for the lack of ERα expression and
HDACs 1, 2 and 3 are overexpressed in breast cancer and correlate
with more aggressive tumor type.37 In agreement, we found that
consumption of HFD by MMTV-PyMT transgenic mice induced
more aggressive, poorly differentiated tumors with increased
HDAC activity. In contrast, in mammary pads from naive animals
or those without tumors, HFD reduced HDAC activity, supporting
the notion that HFD and obesity increase acetylations of histones
with changes in the epigenome.38 Similar to our ﬁndings, it was
previously reported that HFD-induced HDAC activity plays
important roles in epigenetic regulation of tumor suppressor
genes involved in colorectal tumor growth and progression,
Oncogenesis (2015), 1 – 11
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Figure 7. FTY720 reduces breast tumor growth and enhances anticancer effectiveness of TAM in ERα-negative 4T1 syngeneic xenografts.
4T1 cells were surgically implanted into the second mammary fat pads under direct vision. Tumor-bearing mice were randomized into ﬁve
groups 2 days after implantation and then treated with vehicle, FTY720 (1 mg/kg), TAM (25 mg/kg), FTY720 plus TAM or SAHA (intraperitoneal
(i.p.) 20 mg/kg) plus TAM by gavage daily till day 15 (n = 8). (a) Tumor volumes were measured daily. (Insert) Tumor volumes on day 15.
(b) Representative tumors. *P o0.01, #P o0.05 compared with vehicle. (c, d) Immunohistochemical staining of tumor sections for TUNEL
(c) and ERα (d). Scale bar: 20 μm. Quantiﬁcations of TUNEL-positive cells and ERα intensity are shown. *Po 0.05 compared with vehicle or TAM.
(e) HDAC activity in nuclear extracts of tumors was determined and expressed as arbitrary ﬂuorescence units. (f) Expression of ERα in the
tumors was analyzed by quantitative real-time PCR (QPCR) and normalized to Gapdh. (g) Nuclear extract proteins were analyzed by western
blotting with the indicated antibodies. Histone H3 was used as loading control. Data are mean ± s.e.m. *Po 0.01 compared with vehicle
or TAM.

including increased epithelial–mesenchymal transition and tumor
inﬂammation in a xenograft model.39
Several HDAC inhibitors have been developed that restored the
efﬁcacy of hormonal therapy in preclinical models33,34,40 and a few
have advanced to clinical trials.9,41 Combination of the HDAC
inhibitor vorinostat with TAM for patients with ER-positive
metastatic breast cancer progressing on hormonal therapy
showed encouraging reversal of hormone therapy resistance.9
Similar results were obtained in a phase II clinical trial in
postmenopausal women with locally recurrent or metastatic ERpositive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor when combined with the HDAC inhibitor
entinostat,41 leading to a phase III clinical trial that is currently
underway (Clinical-Trials.gov identiﬁer: NCT02115282).
It was originally suggested that the prodrug FTY720 (ﬁngolimod,
Gilenya) approved for human use is phosphorylated at the plasma
membrane by SphK2 to form FTY720-phosphate that acts via S1P
receptors.10,20 However, in this study we have demonstrated that
FTY720 is predominantly phosphorylated to FTY720-P in the
nucleus of both ER-positive and ER-negative breast cancer cells.
Although it has been suggested that phosphorylation of FTY720 by
SphK2 is a requirement for its induction of apoptosis in vitro and
in vivo, the targets for this action have not been identiﬁed.42 We are
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now showing that the active phosphorylated form of FTY720 is a
potent class I HDAC inhibitor. This novel nuclear action of FTY720-P
provides a new mechanism to explain the cytotoxic effects of
FTY720 in cell culture and its preclinical antitumor efﬁcacy in many
xenograft and syngeneic cancer models.43 Moreover, similar to
other HDAC inhibitors, treatment with FTY720 enhances histone
acetylation at the ERα promoter leading to its re-expression, and
sensitizes ER-negative breast cancer cells to TAM therapy. Interestingly, even in HFD-fed PyMT transgenic mice that developed more
advanced, poorly differentiated mammary tumors with increased
HDAC activity and decreased expression of ERα and PR, oral
administration of FTY720 not only suppressed development and
progression of these spontaneous breast tumors, but also reduced
HDAC activity in tumors and concomitantly induced expression of
ERα and PR. Importantly, FTY720 treatment of breast tumor-bearing
mice also induced re-expression of ERα in the tumor and greatly
enhanced the anticancer efﬁcacy of TAM, even more potently than
a known HDAC inhibitor.
FTY720 has multiple beneﬁcial anticancer activities. First, it has
been convincingly shown that the unphosphorylated form is a
potent activator of protein phosphatase 2A, a heterotrimeric
serine/threonine phosphatase that counteracts the activity of
many kinase-driven signaling pathways, including MEK and
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AKT.17,18 In this regard, reduced protein phosphatase 2A activity is
a common event in breast cancer that could predict sensitivity to
FTY720.44 Second, unphosphorylated FTY720 also inhibits and
induces proteasomal degradation of SphK1,45 which is upregulated in breast cancer and correlates with poor prognosis and drug
resistance.46–49 High expression of SphK1 and S1PR1 are also
associated with development of TAM resistance in ER-positive
breast cancer patients.50 Third, because FTY720-P is a functional
antagonist of S1PR1, it can also suppress tumor growth by several
S1PR1-dependent mechanisms. It was shown to decrease
prosurvival/anti-apoptotic signaling from S1PR1 via suppression
of proapoptotic Bim and upregulation of prosurvival Mcl-1
proteins.51 Targeting S1PR1 with FTY720 also interferes with a
major positive feedback loop for persistent STAT3 activation in
breast tumor microenvironment critical for malignant
progression.14 Moreover, FTY720 by interfering with the upregulation of SphK1 and S1PR1 curtails the S1P/SphK1/S1PR1 feedforward ampliﬁcation loop that leads to nuclear factor-κB and
persistent STAT3 activation that play important roles in the link
between chronic inﬂammation and cancer.16 Finally, in this paper
we have uncovered a novel action of FTY720-P as a potent
inhibitor of class I HDACs that acts similarly to other HDAC
inhibitors to reactivate ERα expression and sensitize breast cancer
cells to TAM therapy.
At ﬁrst glance, the immunosuppressive action of FTY720 would
seem to be an undesirable effect in cancer therapy. However, it
has been shown that following treatment of tumor-bearing mice
with FTY720, there was a signiﬁcant reduction in accumulation of
tumor-associated regulatory T cells and an increase in peripheral
blood regulatory T cells, suggesting that FTY720 causes a block in
blood-to-tumor regulatory T-cell recruitment that would allow
more potent antitumor immunity.52 Moreover, treatment of mice
with FTY720 after tumors were established to block new T-cell
trafﬁcking from secondary lymphoid organs still enabled the
increase in the capacity of tumor-inﬁltrating CD8+ T cells to
produce IL-2 and to proliferate and subsequent tumor rejection
induced by combinatorial immunotherapy with anti-CTLA-4 and
anti-PD-L1 monoclonal antibodies.53
As HDAC inhibitors are being developed for treatment of breast
cancer acting through multiple epigenetic pathways, and numerous
clinical trials are underway,21–24 it is not surprising that FTY720 has
such potent anticancer activity. FTY720 has several advantages over
available HDAC inhibitors as potential treatments for breast cancer
patients: it is an orally bioavailable prodrug; it has already been
approved for human use; it regulates expression of only a limited
number of genes (a majority related to cholesterol and sphingolipid
metabolism) compared with other HDAC inhibitors; it has good
pharmacokinetics and a long half-life; it suppresses several survival
and proliferative pathways; it is much less toxic, accumulates in
tumor tissues, and both the phosphorylated and unphosphorylated
forms target important pathways in breast cancer. Hence, we hope
that our studies will pave the way for exploration of new clinical
trials using FTY720 as a prototype of new adjuvant treatment
strategies for hormonal-resistant breast cancer.
MATERIALS AND METHODS
Cell culture and transfection
Human breast cancer cells MCF7 and MDA-MB-231 (ATCC, Manassas, VA,
USA) and murine 4T1 breast cancer cells (Caliper Life Sciences, Waltham,
MA, USA) were cultured and transfected with vector, SphK2 or catalytically
inactive SphK2G212E as previously described.54 SphK2 was downregulated
by transfection with ON-TARGETplus SMARTpool siRNA against SphK2, and
scrambled siRNA (Dharmacon, Lafayette, CO, USA) was used as control.54
Cell growth was determined with WST-8 reagent and absorbance was
measured at 450 nm.55

9
Nuclear extracts and immunoblotting
Nuclear extracts from tissues and cells were prepared and protein
expression determined by immunoblotting as previously described.54
Proteins were separated by SDS–polyacrylamide gel electrophoresis,
transblotted to nitrocellulose and incubated with primary antibodies as
indicated in ﬁgure legends, including rabbit polyclonal antibodies to:
histone H3-K23ac (1:1000 dilution; EMD Millipore, Billerica, MA, USA);
histone H3, H3-K9ac, H4-K5ac and H2B-K12ac (1:1000 dilution; Abcam,
Cambridge, MA, USA); laminA/C, tubulin, p-ERK1/2, HDAC3 and HDAC7
(1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA); HDAC1,
HDAC2 and HDAC8 (1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA); V5 (1:5000 dilution; Life Technologies, Grand Island, NY, USA);
and SphK2 (1:1000 dilution).54 Immunopositive bands were visualized by
enhanced chemiluminescence using secondary antibodies conjugated
with horseradish peroxidase (goat anti-rabbit or anti-mouse, 1:5000
dilution; Jackson ImmunoResearch, West Grove, PA, USA) and SuperSignal West Pico chemiluminescent substrate (Pierce Chemical Co.,
Rockford, IL, USA). Optical densities of bands associated with proteins of
interest were quantiﬁed using AlphaEaseFC software (Alpha Innotech,
Miami, FL, USA) and normalized to the optical densities of their respective
tubulin bands.

Quantiﬁcation of sphingolipids by mass spectrometry
Sphingolipids were measured by liquid chromatography, electrospray ionization–tandem mass spectrometry (4000 QTRAP, AB Sciex,
Framingham, MA, USA).54

HDAC activity measurements
Enzymatic activities of HDACs immunoprecipitated from nuclear extracts
with speciﬁc antibodies were measured with ﬂuorometric assay as
previously described.54.

Quantitative real-time PCR
Total RNA from cells or tumors was isolated with Trizol (life Technologies,
Grand Island, NY, USA) and reverse transcribed with the High Capacity
cDNA Reverse Transcription Kit and pre-mixed primer probe sets from
Applied Biosystems (Foster City, CA, USA). Complementary DNA (cDNA)
was ampliﬁed with the ABI 7900HT (Applied Biosystems).54

Chromatin immunoprecipitation
Cells were crosslinked with 1% formaldehyde for 10 min at 37 °C and then
quenched with glycine, washed with cold phosphate-buffered saline,
suspended in SDS buffer, sonicated and centrifuged. Supernatants were
pre-cleared with protein G-Sepharose beads (GE Healthcare, Piscataway,
NJ, USA) that were blocked with sonicated herring sperm DNA (Promega,
San Louis Obispo, CA, USA) in IP buffer (16.7 mM Tris (pH 8), 16.7 mM NaCl,
1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100, containing 0.05 mg/ml bovine
serum albumin). Chromatin was immunoprecipitated with rabbit polyclonal anti-acetylated H3 or anti-H3 antibodies, or with control rabbit IgG.54
DNA–protein complexes were pulled down with the protein G-Sepharose
beads and then washed with low salt buffer, high salt buffer, LiCl buffer
and Tris-EDTA buffer before eluting with 1% SDS in 0.1 M NaHCO3.
Crosslinks were reversed by heating at 65 °C overnight in 0.3 M NaCl,
followed by proteinase K digestion for 1 h at 55 °C. Input samples were also
similarly treated. DNA was puriﬁed with QIAquick PCR Puriﬁcation Kit
(Qiagen, Germantown, MD, USA). The ER promoter was analyzed by
quantitative real-time PCR using SYBR Green Master Mix (Applied
Biosystems) and the following primers: sense, 5′-GAACCGTCCGCAGCT
CAAGATC-3′; anti-sense, 5′-GTCTGACCGTAGACCTGCGCGTTG-3′. Results
were analyzed relative to input using the ΔCT method. Speciﬁc
endogenous chromatin immunoprecipitation enrichments were all at least
threefold greater than control.

Animal studies
All animal studies were conducted in the Animal Research Core Facility at
VCU School of Medicine in accordance with the institutional guidelines.
Animals were bred and maintained in a pathogen-free environment and all
procedures were approved by the VCU Institutional Animal Care and Use
Committee that is accredited by the Association for Assessment and
Accreditation of laboratory Animal Care. All mice were kept on a 12-h light/
dark cycle with free access to food.
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Male MMTV-PyMT mice on a FVB/N background (Jackson Laboratories,
Bar Harbor, MD, USA) were randomly bred with normal FVB/N females to
obtain females heterozygous for the PyMT oncogene. Mice were fed a
normal diet or HFD (TD.88137; Harlan Laboratories, Indianapolis, IN, USA)
containing cholesterol (0.2%), total fat (21% by weight; 42% kcal from fat),
saturated fatty acids (460% of total fatty acids), sucrose (34% by weight),
protein (17.3% by weight) and carbohydrate (48.5% by weight). Palpable
mammary tumors developed as early as 6 weeks of age. Tumor size was
measured with calipers every 3 days and total tumor volume was
estimated by the cylinder formula.
For the syngeneic breast cancer model, 4T1 mouse mammary cancer
cells were surgically implanted in the upper fat pads of female BALB/c mice
(8 to 12 weeks of age, Jackson Laboratories) under direct vision as
described previously.35,36 Tumor-bearing mice were randomized 2 days
after implantation into ﬁve treatment groups: vehicle, FTY720 (p.o. 1 mg/
kg, Cayman Chemical Company, Ann Arbor, MI, USA), TAM (intraperitoneal
25 mg/kg; Sigma-Aldrich, St Louis, MO, USA), FTY720 plus TAM, and SAHA
(intraperitoneal 20 mg/kg; Sigma-Aldrich) plus TAM. Tumors were measured regularly and tumor volumes calculated. At the indicated times,
animals were killed by exsanguination, blood was collected, tumors
excised, weighed, ﬁxed in 10% neutral buffered formalin and embedded in
parafﬁn or frozen in liquid nitrogen for morphological and immunoﬂuorescence analyses.

Histopathological analysis
Tissue slices (5 μm) were stained with hematoxylin and eosin for
morphological analysis. Frozen tissue samples were embedded in Optimal
Cutting Medium (OCT 4583; Sakura Finetek, Torrance, CA, USA) for
immunoﬂuorescence analysis. Parafﬁn-embedded slides were deparafﬁnized, and antigen unmasking was carried out by microwave heating in
citrate buffer for 20 min. Slides were incubated with 3% H2O2 and then
with goat or horse serum (DAKO, Carpinteria, CA, USA) for 30 min at room
temperature. After washing with phosphate-buffered saline, slides were
incubated at 4 °C overnight with the following primary antibodies: ERα
(Santa Cruz), H3-K9ac (Abcam), cyclin D1 (Cell Signaling) and Ki67 (Dako).
Biotinylated secondary antibodies were added and incubated at room
temperature for 20 min. After 5 min with streptavidin-HRP, sections were
stained with DAB substrate and counterstained with hematoxylin. Slides
were examined with a Zeiss Axioimager A1 (Jena, Germany) and images
captured with an AxioCam MRc camera.

Gene expression microarrays
Total RNA was extracted using the MagMAX-96 for Microarrays Total RNA
Isolation Kit (Life Technologies) in an automated manner using the
MagMAX Express magnetic particle processor. RNA purity integrity was
assessed by spectrophotometry at 260, 270 and 280 nm and by RNA 6000
Nano LabChips with the 2100 Bioanalyzer (Agilent Technologies,
Carpenteria, CA, USA).56 Single-strand cDNA was synthesized from
500 ng total RNA primed with a T7-(dT24) oligonucleotide. Second-strand
cDNA synthesis was performed with Escherichia coli DNA Polymerase I, and
cRNA biotinylated by in vitro transcription using the GeneChip 3' in vitro
transcription Express Kit (Affymetrix, Santa Clara, CA, USA). After incubation
at 37 °C for 16 h, labeled cRNA was puriﬁed using the GeneChip Sample
Cleanup Module. Fragmented cRNA (10 μg) was hybridized on the
GeneChip HG-U133A 2.0 array for 16 h at 60 r.p.m. in a 45 °C hybridization
oven. Arrays were washed and stained with streptavidin phycoerythrin
(Life Technologies) in the Affymetrix ﬂuidics workstation. Every chip was
scanned at a high resolution on the Affymetrix GeneChip Scanner 3000 7G
and raw intensities for every probe were stored in electronic ﬁles by the
GeneChip Operating Software v1.4.36 Overall quality of each array was
assessed by monitoring the 3′/5′ ratios for the housekeeping gene,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the percentage of
‘Present’ genes (%P). Arrays exhibiting GAPDH 3′/5′ o3.0 and %P 440%
were considered good-quality arrays. For microarray data analyses,
background correction, normalization and estimation of probe set
expression summaries and ﬁltering and hierarchical cluster analyses were
performed using the log-scale Robust Multi-array Analysis method57 and
BRB-ArrayTools v3.1.0 (NCI, Bethesda, MD, USA), respectively. Differentially
expressed genes among the classes were identiﬁed by t-test analyses. To
adjust for multiple hypotheses testing, the resulting P-values were used to
obtain the false discovery rates using the q-value method. All analyses
were performed on the R environment using functions provided by the
BioConductor packages.58
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Statistical analysis
Statistical analysis was performed using unpaired two-tailed Student’s
t-test for comparison of two groups. Po 0.05 was considered signiﬁcant.
Experiments were repeated at least three times with consistent results. For
animal studies, measurements were blind with respect to group
assignments.
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